Cogent Biosciences (COGT) EV/EBIT: History & Chart

Cogent Biosciences, Inc.(COGT)

Biotechnology · Waltham, MA

$31.07+0.20 (+0.65%)

Delayed quote: Oct 6, 2026, 9:30 AM EDT

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.

Waltham, MA

258 employees

www.cogentbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Andrew R. Robbins

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Cogent Biosciences, Inc. (COGT)	$5.31B	N/A	N/A	N/A	N/A
Doximity, Inc. (DOCS)vs ›	$5.35B	26.19x	27.68x	39.35x	54.79x
Merit Medical Systems, Inc. (MMSI)vs ›	$5.20B	27.69x	27.45x	34.84x	44.16x
Scholar Rock Holding Corporation (SRRK)vs ›	$5.20B	N/A	N/A	N/A	N/A
Erasca, Inc. (ERAS)vs ›	$5.11B	N/A	N/A	N/A	N/A
CRISPR Therapeutics AG (CRSP)vs ›	$5.84B	N/A	13.54x	42.19x	42.19x
BillionToOne, Inc. (BLLN)vs ›	$4.96B	105.22x	157.20x	157.20x	157.20x
Dianthus Therapeutics, Inc. (DNTH)vs ›	$4.92B	N/A	N/A	N/A	N/A
Adaptive Biotechnologies Corporation (ADPT)vs ›	$4.84B	N/A	N/A	N/A	N/A
Definium Therapeutics, Inc. (DFTX)vs ›	$4.81B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/EBIT RATIO

TTM

Cogent Biosciences, Inc. (COGT)

$5.31B

N/A

Doximity, Inc. (DOCS)vs ›

$5.35B

26.19x

27.68x

39.35x